Janus Henderson Group’s Viking Therapeutics VKTX Stock Holding History

Janus Henderson Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Hold	45,700	–	–	﹤0.01%	1502
2025 Q4	$1.61M	Hold	45,700	–	–	﹤0.01%	1444
2025 Q3	$1.2M	Hold	45,700	–	–	﹤0.01%	1564
2025 Q2	$1.21M	Hold	45,700	–	–	﹤0.01%	1524
2025 Q1	$1.17M	Hold	45,700	–	–	﹤0.01%	1550
2024 Q4	$1.84M	Hold	45,700	–	–	﹤0.01%	1357
2024 Q3	$2.89M	Hold	45,700	–	–	﹤0.01%	1130
2024 Q2	$2.42M	Buy	45,700 +4,537	+11%	+$297K	﹤0.01%	1167
2024 Q1	$3.37M	Hold	41,163	–	–	﹤0.01%	1040
2023 Q4	$766K	Sell	41,163 -80	-0.2%	-$1.05K	﹤0.01%	1780
2023 Q3	$457K	Buy	41,243 +14	+0%	+$200	﹤0.01%	1968
2023 Q2	$668K	Sell	41,229 -349,907	-89%	-$7.33M	﹤0.01%	1830
2023 Q1	$6.52M	Buy	+391,136	New	+$4.04M	﹤0.01%	801
2022 Q2	–	Sell	-13,409	Closed	-$40K	–	2693
2022 Q1	$40K	Hold	13,409	–	–	﹤0.01%	2625
2021 Q4	$62K	Buy	+13,409	New	+$75.2K	﹤0.01%	2531
2018 Q4	–	Sell	-891,442	Closed	-$15.5M	–	1426
2018 Q3	$15.5M	Sell	891,442 -1,168,844	-57%	-$13.9M	0.01%	857
2018 Q2	$19.6M	Buy	+2,060,286	New	+$13.7M	0.01%	806

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Janus Henderson Group's VKTX Position: Q1 2026 in Review

Janus Henderson Group held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 45,700 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

Janus Henderson Group first reported a position in VKTX in Q2 2018 and has held it in 17 quarters since. The position peaked at $19.6M in Q2 2018. 414 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Janus Henderson Group held 45,700 shares of Viking Therapeutics worth $1.49M as of Q1 2026.
Janus Henderson Group left its Viking Therapeutics share count unchanged in Q1 2026.
Viking Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1502 holding.
Janus Henderson Group first reported a position in Viking Therapeutics in Q2 2018 and has held it in 17 quarters since.
Janus Henderson Group's Viking Therapeutics position peaked at $19.6M in Q2 2018.
414 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.